Jazz Pharma Presents Data for Treatment of EDS Symptoms in Adults with Narcolepsy


Jazz Pharmaceuticals presented data this week at SLEEP 2014 from its Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy.


In the study, all primary and secondary endpoints were met and patients treated with JZP-110 experienced statistically significant improvements in objective and subjective symptoms of EDS. Based on these data, Jazz Pharmaceuticals plans to evaluate JZP-110 in Phase 3 clinical studies in patients with EDS associated with narcolepsy and in patients with EDS associated with obstructive sleep apnea (OSA), pending discussions with regulatory agencies.


These data were presented this week at a late-breaker session during SLEEP 2014, the 28th Annual Meeting of the Associated Professional Sleep Societies (APSS), in Minneapolis, Minn. “We are committed to developing and commercializing new and differentiated therapies that address unmet patient needs in sleep medicine, and we believe, based on the encouraging results from early clinical trials, that JZP-110 has the potential to significantly help people with narcolepsy and OSA who are experiencing EDS,” said Jeffrey Tobias, MD, executive vice president, Research and Development, and chief medical officer, Jazz Pharmaceuticals. “As one of the newest additions to our growing sleep clinical development pipeline, we look forward to advancing the Phase 3 clinical program for this product candidate.”

The post Jazz Pharma Presents Data for Treatment of EDS Symptoms in Adults with Narcolepsy appeared first on Sleep Diagnosis and Therapy.

Frost & Sullivan Concludes Time is Ripe for Sleep Market


Citing the “large cohort of undiagnosed people with OSA across the globe,” Frost & Sullivan analysts recently identified the sleep world as a “highly attractive market for investments.”


The new analysis from Frost & Sullivan’s Technology Breakthroughs in Sleep Apnea finds that the time is ripe for stakeholders to integrate their efforts and develop a standard platform to diagnose and treat sleep apnea patients.


“Current treatments for sleep apnea include surgery to correct static obstructions, the use of continuous positive airway pressure (CPAP) devices to supply air, and other devices that help keep the airway open,” said Frost & Sullivan Technical Insights team leader Saju John Mathew. “There are also over 30 different drugs in the market that address OSA issues by increasing the tone of the upper airways and ventilator drive. Other drugs work to reacidify the blood and force the body to breathe more often, balancing the effect of hyperventilation.”


According to Frost & Sullivan, a key challenge facing the market is the lack of qualified personnel, such as pulmonologists and otolaryngologists, to diagnose sleep apnea in a timely manner. In addition, poor compliance with CPAP devices – “even though it is safer and more effective than any other surgical therapy – has resulted in sleep apnea and its associated illnesses recurring among patients.”


Analysts add that the development of more “ergonomic CPAP devices will help increase patient ability to adhere to sleep therapy. The market is also seeing a rise in newer technologies that replace elaborate practices, target patient comfort to improve compliance, and help drive acceptance of sleep monitoring devices. This includes mandibular repositioning devices, which are cheaper than CPAP devices and more effective than tongue retaining devices; neuromodulators that are being developed with increasingly smaller footprints resulting in small incisions.”

The post Frost & Sullivan Concludes Time is Ripe for Sleep Market appeared first on Sleep Diagnosis and Therapy.